Targeting Immunosuppressive MARCO+ Myeloid Cells to Unleash Anti-Tumor Immunity
Time: 3:45 pm
day: Day One
Details:
- Pionyr identified the Macrophage Receptor with a Collagenous Structure (MARCO) as a potential myeloid reprogramming target and developing a humanized anti-MARCO monoclonal antibody (mAb), termed PY265
- PY265 induced reprogramming of M2-like macrophages and immunosuppressive mMDSCs to M1-like macrophages and pro-inflammatory monocytes, leading to pro-inflammatory immune activation
- PY265m, a surrogate antibody specific to mouse MARCO, demonstrated significant anti-tumor activity both as a single agent in CPI-sensitive syngeneic tumor models and in combination with anti-PD-1 in CPIresistant syngeneic tumor models
